blisibimod
Peptideexperimental
Blisibimod is a selective antagonist of B-cell activating factor, being developed by Anthera Pharmaceuticals as a treatment for systemic lupus erythematosus. It is currently under active investigation in clinical trials. — Wikipedia
Clinical trial activity
11 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
7
Phase 3
6
Phase 4
0
Earliest trial started Oct 1, 2004 (NCT02443506)
Timeline
Indications
Mechanism of action
TNFSF13B inhibitor
Binds to both membrane-bound and soluble BAFF.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBlisibimod ↗
- ChEMBLCHEMBL2107877 ↗
Also known as
- a-623
- a-623
- a-623
- a-623
- amg 623
- amg623 peptibody
- blisibimod
- blisibimod
- blisibimod
- blisibimod
- blisibimod
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02514967 | Phase 3 | Jun 1, 2016 | Anthera Pharmaceuticals |
| NCT01609452 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2015 | Anthera Pharmaceuticals |
| NCT02074020 | Phase 3 | Dec 1, 2015 | Anthera Pharmaceuticals |
| NCT01598857 | Phase 2 | Dec 1, 2014 | Anthera Pharmaceuticals |
| NCT02052219 | Phase 3 | Oct 1, 2014 | Anthera Pharmaceuticals |
| NCT02062684 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2013 | Anthera Pharmaceuticals |
| NCT01395745 | Phase 3 | Feb 1, 2013 | Anthera Pharmaceuticals |
| NCT01305746 | Phase 2 | Apr 1, 2011 | Anthera Pharmaceuticals |
| NCT01162681 | Phase 2 | Jul 1, 2010 | Anthera Pharmaceuticals |
| NCT02411136 | Phase 1 | May 1, 2005 | Amgen |
| NCT02443506 | Phase 1 | Oct 1, 2004 | Amgen |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Anthera Pharmaceuticals | For profit | 9 | 9 | 2 | 2010 |
| Amgen | For profit | 2 | 2 | 1 | 2004 |
2 organizations
Page 1 / 1